Apogee Therapeutics Statistics
Total Valuation
APGE has a market cap or net worth of $6.46 billion. The enterprise value is $5.21 billion.
| Market Cap | 6.46B |
| Enterprise Value | 5.21B |
Important Dates
The last earnings date was Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
APGE has 74.95 million shares outstanding. The number of shares has increased by 11.13% in one year.
| Current Share Class | 61.46M |
| Shares Outstanding | 74.95M |
| Shares Change (YoY) | +11.13% |
| Shares Change (QoQ) | +3.43% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 94.85% |
| Float | 57.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 775.17 |
| PB Ratio | 5.11 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.59, with a Debt / Equity ratio of 0.01.
| Current Ratio | 32.59 |
| Quick Ratio | 32.39 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.47% and return on invested capital (ROIC) is -19.58%.
| Return on Equity (ROE) | -28.47% |
| Return on Assets (ROA) | -19.01% |
| Return on Invested Capital (ROIC) | -19.58% |
| Return on Capital Employed (ROCE) | -24.21% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.05M |
| Employee Count | 261 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, APGE has paid $274,000 in taxes.
| Income Tax | 274,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +93.47% in the last 52 weeks. The beta is 0.62, so APGE's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +93.47% |
| 50-Day Moving Average | 84.49 |
| 200-Day Moving Average | 68.61 |
| Relative Strength Index (RSI) | 53.26 |
| Average Volume (20 Days) | 1,056,674 |
Short Selling Information
The latest short interest is 10.53 million, so 14.04% of the outstanding shares have been sold short.
| Short Interest | 10.53M |
| Short Previous Month | 9.37M |
| Short % of Shares Out | 14.04% |
| Short % of Float | 18.20% |
| Short Ratio (days to cover) | 12.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -305.27M |
| Pretax Income | -274.34M |
| Net Income | -274.62M |
| EBITDA | -303.65M |
| EBIT | -305.27M |
| Earnings Per Share (EPS) | -$4.32 |
Balance Sheet
The company has $1.06 billion in cash and $8.05 million in debt, with a net cash position of $1.25 billion or $16.68 per share.
| Cash & Cash Equivalents | 1.06B |
| Total Debt | 8.05M |
| Net Cash | 1.25B |
| Net Cash Per Share | $16.68 |
| Equity (Book Value) | 1.26B |
| Book Value Per Share | 16.87 |
| Working Capital | 1.04B |
Cash Flow
In the last 12 months, operating cash flow was -$234.54 million and capital expenditures -$830,000, giving a free cash flow of -$235.37 million.
| Operating Cash Flow | -234.54M |
| Capital Expenditures | -830,000 |
| Depreciation & Amortization | 1.62M |
| Net Borrowing | n/a |
| Free Cash Flow | -235.37M |
| FCF Per Share | -$3.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.13% |
| Shareholder Yield | -11.13% |
| Earnings Yield | -4.25% |
| FCF Yield | -3.64% |
Analyst Forecast
The average price target for APGE is $119.50, which is 38.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $119.50 |
| Price Target Difference | 38.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |